Last Updated: November 20, 2026

Ibuprofen; phenylephrine hydrochloride - Generic Drug Details

« Back to Dashboard


What are the generic sources for ibuprofen; phenylephrine hydrochloride and what is the scope of freedom to operate?

Ibuprofen; phenylephrine hydrochloride is the generic ingredient in two branded drugs marketed by Haleon Us Holdings and Perrigo R And D, and is included in two NDAs. Additional information is available in the individual branded drug profile pages.

Three suppliers are listed for this compound.

Summary for ibuprofen; phenylephrine hydrochloride
Recent Clinical Trials for ibuprofen; phenylephrine hydrochloride

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of North Carolina, Chapel HillPHASE4
Ache Laboratorios Farmaceuticos S.A.Phase 3
PfizerPhase 3

See all ibuprofen; phenylephrine hydrochloride clinical trials

Pharmacology for ibuprofen; phenylephrine hydrochloride
Anatomical Therapeutic Chemical (ATC) Classes for ibuprofen; phenylephrine hydrochloride
C01CA Adrenergic and dopaminergic agents
C01C CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
C01 CARDIAC THERAPY
C Cardiovascular system
C01EB Other cardiac preparations
C01E OTHER CARDIAC PREPARATIONS
C01 CARDIAC THERAPY
C Cardiovascular system
C05AX Other agents for treatment of hemorrhoids and anal fissures for topical use
C05A AGENTS FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE
C05 VASOPROTECTIVES
C Cardiovascular system
G02CC Antiinflammatory products for vaginal administration
G02C OTHER GYNECOLOGICALS
G02 OTHER GYNECOLOGICALS
G Genito-urinary system and sex hormones
M01AE Propionic acid derivatives
M01A ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
M01 ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M Musculo-skeletal system
M02AA Antiinflammatory preparations, non-steroids for topical use
M02A TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
M Musculo-skeletal system
R01AA Sympathomimetics, plain
R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01 NASAL PREPARATIONS
R Respiratory system
R01AB Sympathomimetics, combinations excl. corticosteroids
R01A DECONGESTANTS AND OTHER NASAL PREPARATIONS FOR TOPICAL USE
R01 NASAL PREPARATIONS
R Respiratory system
R01BA Sympathomimetics
R01B NASAL DECONGESTANTS FOR SYSTEMIC USE
R01 NASAL PREPARATIONS
R Respiratory system
R02AX Other throat preparations
R02A THROAT PREPARATIONS
R02 THROAT PREPARATIONS
R Respiratory system
S01FB Sympathomimetics excl. antiglaucoma preparations
S01F MYDRIATICS AND CYCLOPLEGICS
S01 OPHTHALMOLOGICALS
S Sensory organs
S01GA Sympathomimetics used as decongestants
S01G DECONGESTANTS AND ANTIALLERGICS
S01 OPHTHALMOLOGICALS
S Sensory organs

US Patents and Regulatory Information for ibuprofen; phenylephrine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Perrigo R And D IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE ibuprofen; phenylephrine hydrochloride TABLET;ORAL 203200-001 Jul 3, 2014 OTC No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Haleon Us Holdings ADVIL CONGESTION RELIEF ibuprofen; phenylephrine hydrochloride TABLET;ORAL 022565-001 May 27, 2010 OTC Yes Yes ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Ibuprofen and Phenylephrine Hydrochloride Market Dynamics, Patent Risk, and Financial Trajectory

Last updated: November 11, 2026

The ibuprofen and phenylephrine hydrochloride combination is a mature over-the-counter (OTC) cold, flu, sinus, and pain product category. Its commercial value comes from brand recognition, retail distribution, seasonal demand, and convenience rather than pharmaceutical exclusivity. Ibuprofen supplies analgesic and antipyretic activity; phenylephrine hydrochloride is used as an oral nasal decongestant.

The category faces a material regulatory risk in the United States because FDA concluded that oral phenylephrine is not effective at the recommended OTC dose. The FDA proposed removing oral phenylephrine from the OTC monograph in 2024, but the proposal did not immediately make existing products unlawful or require an immediate market withdrawal [1]. The likely financial effect is a shift toward reformulation, product relaunches, and substitution with other decongestant or symptom-relief products.

What is the ibuprofen and phenylephrine hydrochloride drug combination?

Ibuprofen is a nonsteroidal anti-inflammatory drug used for pain and fever. Phenylephrine hydrochloride is an alpha-adrenergic agonist marketed as an oral nasal decongestant.

Fixed-dose products are sold in several markets under brand names such as:

Product type Typical active ingredients Primary consumer claim
Cold and flu tablets Ibuprofen plus phenylephrine hydrochloride Pain, fever, congestion
Sinus products Ibuprofen plus phenylephrine hydrochloride Sinus pressure, headache, blocked nose
Multi-symptom sachets Ibuprofen plus phenylephrine, sometimes with other ingredients Cold and flu symptom relief
Private-label tablets Ibuprofen plus phenylephrine hydrochloride Lower-cost equivalent to branded products

The exact strength, dosage form, labeling, and regulatory status vary by country. In many products, ibuprofen is present at 200 mg per tablet, while phenylephrine hydrochloride is commonly present at a low single-digit milligram dose. Product labels must be reviewed by jurisdiction because formulations differ.

How large is the market for ibuprofen and phenylephrine products?

There is no single publicly reported global revenue line for the fixed-dose ibuprofen-phenylephrine combination. Manufacturers generally report the products within broader categories such as consumer health, pain relief, respiratory health, or cold and flu.

The addressable market is supported by four demand pools:

  1. OTC analgesics, led by ibuprofen and acetaminophen.
  2. Cold, cough, and flu treatments.
  3. Nasal congestion and sinus remedies.
  4. Seasonal multi-symptom products.

The combination competes with products containing ibuprofen and pseudoephedrine, acetaminophen and phenylephrine, acetaminophen and pseudoephedrine, antihistamine combinations, nasal sprays, and single-ingredient analgesics.

What drives revenue?

Revenue is concentrated in the Northern Hemisphere winter season and rises with respiratory-virus activity. Other drivers include:

  • Retailer shelf placement.
  • National advertising.
  • Private-label penetration.
  • Pricing and promotional intensity.
  • Consumer preference for one-tablet symptom relief.
  • Availability of pseudoephedrine products.
  • Regulatory treatment of oral phenylephrine.
  • Supply-chain execution during influenza and respiratory-virus peaks.

The combination has a relatively low manufacturing cost. Gross-to-net performance is determined by retailer discounts, promotions, rebates, listing fees, and brand support rather than by high unit economics.

What is the financial trajectory for ibuprofen and phenylephrine products?

The financial trajectory is mature-to-declining for products dependent on oral phenylephrine in the United States. International performance is more mixed because regulatory conclusions, product formulations, and consumer demand differ by market.

Base-case trajectory

The most likely base case is:

Period Expected commercial pattern
Near term Stable or seasonal revenue, with U.S. regulatory uncertainty and inventory management
Medium term Decline in U.S. oral phenylephrine sales, greater private-label pressure, and reformulation
Longer term Migration toward ibuprofen-only, ibuprofen-pseudoephedrine, nasal-decongestant, or non-decongestant products

The ibuprofen component retains value because its clinical role is independent of phenylephrine. A manufacturer can preserve part of the franchise by selling an ibuprofen-only product or moving consumers to an alternative cold-and-flu formulation.

Revenue exposure by product architecture

Product architecture Financial risk Likely response
Ibuprofen-only Low Maintain distribution and pricing
Ibuprofen plus phenylephrine High in the U.S. Reformulate, rebrand, or withdraw
Ibuprofen plus pseudoephedrine Medium Regulatory and retail-channel constraints
Ibuprofen plus antihistamine Medium Position for nighttime or multi-symptom use
Ibuprofen plus nasal spray or separate decongestant Medium Convert to a dual-product regimen
Private-label ibuprofen plus phenylephrine High Rapid delisting or replacement if monograph status changes

Public companies do not normally disclose revenue from this specific combination. Relevant financial exposure is therefore best assessed through respiratory-health portfolios and brand-level commentary from companies such as Reckitt, Haleon, Kenvue, Perrigo, and regional OTC manufacturers. Reckitt’s Nurofen and cold-and-flu portfolio, Haleon’s consumer-health brands, and retailer private-label products provide relevant commercial comparables, but reported figures should not be treated as revenue attributable solely to ibuprofen plus phenylephrine [2-5].

What regulatory risk affects oral phenylephrine in the United States?

The principal U.S. risk is FDA’s finding that oral phenylephrine is not effective as a nasal decongestant at the current OTC dosage.

In September 2023, an FDA advisory committee concluded that available data did not support the effectiveness of oral phenylephrine as an OTC nasal decongestant [1]. In November 2024, FDA proposed an administrative order to remove oral phenylephrine from the OTC monograph because the ingredient did not meet the applicable effectiveness standard [6].

The proposal does not apply in the same way to phenylephrine delivered through nasal sprays. It also does not eliminate ibuprofen from the market. The regulatory effect is directed at oral phenylephrine’s decongestant claim and products relying on that ingredient.

What happens if FDA removes oral phenylephrine?

Manufacturers would generally face several commercial choices:

  • Remove phenylephrine and market an ibuprofen-only product.
  • Replace phenylephrine with another active ingredient where legally and commercially feasible.
  • Shift to a pseudoephedrine-containing product.
  • Use a nasal decongestant as a separate product.
  • Preserve the product as an analgesic and revise its claims.
  • Discontinue the product and redirect marketing spend.

A replacement with pseudoephedrine is not a simple one-for-one substitution. Pseudoephedrine is subject to sales controls, purchase limits, retailer restrictions, and diversion concerns in the United States under the Combat Methamphetamine Epidemic Act [7]. Those controls can reduce convenience and limit mass-market distribution.

What is the FDA status of ibuprofen and phenylephrine products?

Ibuprofen is an established OTC active ingredient under FDA’s analgesic, antipyretic, and antirheumatic monograph framework. Oral phenylephrine has historically been included in the OTC monograph framework for nasal decongestants, but its continued status is subject to FDA’s proposed removal process.

Products marketed under an OTC monograph generally do not have the same product-specific approval structure as a new prescription drug. Their commercial legality depends on conformity with the applicable monograph, labeling requirements, current administrative orders, and general FDA requirements.

A manufacturer may also market a product through an approved new drug application, but most mature OTC combination products rely on monograph or legacy regulatory pathways rather than product-specific novel-drug exclusivity.

What patents protect ibuprofen and phenylephrine hydrochloride products?

The core active ingredients are old and do not have meaningful composition-of-matter exclusivity.

Protection category Commercial relevance
Ibuprofen active ingredient Core compound protection expired decades ago
Phenylephrine hydrochloride active ingredient Core compound protection expired decades ago
Fixed-dose combination Potential formulation or dosage-form protection, usually limited
Tablet coating or release profile Possible formulation patents, depending on product
Manufacturing process Possible process patents, often difficult to enforce against ordinary tablet production
Packaging and trade dress Trademark and unfair-competition protection
Brand name Potentially durable trademark protection
OTC labeling Regulatory compliance requirement, not patent exclusivity
Consumer advertising claims Subject to FDA and FTC requirements

The main defensible assets are usually trademarks, retailer relationships, distribution, formulation know-how, packaging, and advertising. A patent covering a specific dosage form, controlled-release profile, taste-masking system, or manufacturing process may exist, but it would not normally restore exclusivity over the active ingredients themselves.

How strong is the patent estate?

The patent estate is generally weak for the basic fixed-dose combination and stronger for narrow product implementations.

A useful risk ranking is:

IP asset Relative strength
Basic ibuprofen plus phenylephrine composition Low
Specific extended-release formulation Medium
Novel delivery system Medium to high if technically differentiated
Manufacturing process Low to medium
Brand and trade dress Medium to high commercially
Regulatory exclusivity Low for standard monograph products

Patent analysis must be performed at the product, country, dosage-form, and assignee level. A global conclusion cannot be drawn from the ingredient names alone.

When does ibuprofen and phenylephrine lose exclusivity?

The active ingredients have already lost pharmaceutical exclusivity. Standard immediate-release tablets can be manufactured by multiple suppliers, subject to regulatory compliance and quality requirements.

There is no single global patent expiration date for the combination. Relevant protection may consist of individual patents with different filing dates, jurisdictions, claims, and expiration periods. In the United States, a post-1995 utility patent generally expires 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment and other statutory modifications [8].

For mature OTC products, the commercial loss of exclusivity usually occurs through:

  • Entry of store brands.
  • Multiple approved or monograph-compliant competitors.
  • Retail price competition.
  • Product substitution.
  • Loss of shelf space.
  • Reduced consumer advertising.

Are there Paragraph IV challenges for ibuprofen and phenylephrine products?

Paragraph IV litigation is unlikely to be the principal competitive mechanism for standard ibuprofen-phenylephrine OTC products.

Paragraph IV certifications apply to abbreviated new drug applications referencing listed drugs with relevant Orange Book patents. Many OTC monograph products are not protected through the same Orange Book patent framework as branded prescription drugs. A product may have an NDA and Orange Book listing, but the presence of an Orange Book entry depends on the specific product and regulatory history.

For a conventional OTC combination, market entry is more likely to arise through:

  • OTC monograph compliance.
  • An abbreviated application where applicable.
  • Private-label manufacturing.
  • State and federal labeling compliance.
  • Trademark clearance.
  • Retail distribution agreements.

The absence of a major Paragraph IV campaign does not mean there is no competition. It means competition is more likely to occur through regulatory and commercial pathways than through classic patent litigation.

What is the Orange Book status of ibuprofen and phenylephrine?

There is no single Orange Book status for the ingredient combination. Status depends on the specific manufacturer, product, NDA, dosage form, and listing history.

A product marketed under the OTC monograph system may have no relevant Orange Book patent listing. An NDA-based product could have an Orange Book listing, but that must be verified against the FDA’s current Approved Drug Products with Therapeutic Equivalence Evaluations database and product-specific FDA records [9].

The commercial implication is direct: standard generic-entry analysis based only on Orange Book patents can materially understate OTC competition.

What litigation and settlement risks affect the category?

The principal legal risks are usually:

  • Product-liability claims involving ibuprofen gastrointestinal, renal, or cardiovascular risks.
  • Labeling and advertising claims involving congestion relief.
  • FTC challenges to unsupported efficacy claims.
  • Trademark disputes.
  • Packaging and trade-dress disputes.
  • Consumer class actions concerning product performance.
  • Manufacturing and supply agreements.
  • Regulatory challenges to oral phenylephrine.

Patent litigation is less likely to determine category economics than regulatory action against phenylephrine efficacy claims. A settlement agreement involving a specific product cannot be generalized to the entire ingredient class.

Which companies compete in ibuprofen and phenylephrine?

Competition is fragmented across branded OTC companies, regional manufacturers, and retailers.

Branded manufacturers

Relevant participants include:

  • Reckitt, through Nurofen and related cold-and-flu products in selected markets.
  • Haleon, through its consumer-health portfolio and regional cold remedies.
  • Kenvue, through its analgesic and cold-health brands.
  • Perrigo, through store-brand and contract-manufactured OTC products.
  • Regional pharmaceutical companies and pharmacy chains.

Brand ownership differs by country. A brand sold by one company in Europe may have a different owner or licensee elsewhere.

Private-label manufacturers

Private-label products increase price pressure because the active ingredients are inexpensive, manufacturing technology is widely available, and retailers can switch suppliers. Private-label penetration is highest where consumers view the product as a functional commodity and brand loyalty is limited.

How does ibuprofen plus phenylephrine compare with competing products?

Product Main benefit Regulatory position Commercial outlook
Ibuprofen plus phenylephrine Pain, fever, congestion U.S. oral phenylephrine risk Vulnerable to reformulation
Ibuprofen plus pseudoephedrine Pain, fever, congestion Retail and controlled-sale restrictions Stronger decongestant proposition, lower convenience
Acetaminophen plus phenylephrine Pain, fever, congestion Same oral phenylephrine risk Similar U.S. exposure
Ibuprofen alone Pain and fever Established OTC pathway Durable, highly competitive
Nasal phenylephrine plus oral ibuprofen Local congestion relief plus pain Different delivery route Potential substitution strategy
Ibuprofen plus antihistamine Pain with allergy or nighttime positioning Ingredient-specific Niche and seasonal

The combination’s main competitive advantage is convenience. Its principal weakness is dependence on an oral decongestant whose efficacy has been challenged by FDA.

What generic launch scenarios exist?

Scenario 1: Existing product continues

If FDA does not immediately finalize removal or permits a transition period, companies may continue selling existing products while reducing inventory and testing replacement formulations.

Scenario 2: Phenylephrine is removed from the label

Manufacturers may relaunch the product as ibuprofen-only. Revenue per unit would likely decline because the product would lose its congestion claim and compete directly with commodity analgesics.

Scenario 3: Switch to pseudoephedrine

This could preserve the multi-symptom proposition but would reduce convenience and increase compliance costs. Retail availability could be narrower.

Scenario 4: Product discontinuation

Low-volume brands and private-label items may be discontinued rather than reformulated. Manufacturers may redirect capacity to ibuprofen-only, acetaminophen-based, or topical decongestant products.

Scenario 5: International divergence

Products may remain available outside the United States where local regulators do not adopt the same conclusion or where the combination has a different approval status. This creates country-level portfolio divergence and complicates global packaging and supply planning.

What manufacturing and IP barriers affect entry?

Manufacturing barriers are moderate, not high. Standard immediate-release tablets use established processes and widely available active pharmaceutical ingredients.

Operational barriers include:

  • Qualified ibuprofen and phenylephrine suppliers.
  • API impurity controls.
  • Tablet uniformity and content testing.
  • Stability data.
  • Packaging that protects against moisture.
  • Child-resistant packaging where required.
  • Country-specific labeling.
  • Pharmacovigilance and complaint handling.
  • Retailer qualification.
  • Seasonal inventory planning.

The more important barriers are commercial. A new entrant must obtain retail shelf space, meet retailer service levels, manage seasonal demand, and compete with established brands and private labels.

What is the investment outlook for the category?

The category is a low-growth or declining opportunity when defined narrowly as oral ibuprofen plus phenylephrine. Investment value is higher in adjacent platforms:

  • Ibuprofen-only brands with strong distribution.
  • Multi-symptom products not dependent on oral phenylephrine.
  • Nasal delivery systems.
  • Pediatric and liquid formulations with differentiated dosing.
  • Private-label manufacturing.
  • Regional brands in markets with stable regulatory treatment.
  • Reformulation capabilities and rapid OTC regulatory execution.

Revenue exposure should be modeled at the brand and country level. A company with a small phenylephrine combination line but a large ibuprofen franchise may face limited enterprise-wide damage. A retailer or manufacturer concentrated in oral phenylephrine cold products faces greater product-obsolescence risk.

Key Takeaways

  • Ibuprofen and phenylephrine hydrochloride products are mature OTC combinations with low active-ingredient exclusivity.
  • The principal U.S. commercial risk is FDA’s proposed removal of oral phenylephrine from the OTC monograph.
  • Ibuprofen retains standalone value even if the combination loses its congestion claim.
  • Private-label competition and retailer substitution are more important than Paragraph IV patent litigation.
  • There is no universal patent expiration date or Orange Book status for the combination.
  • Financial reporting generally does not isolate revenue from ibuprofen plus phenylephrine.
  • The strongest commercial assets are brands, distribution, retailer access, formulation know-how, and manufacturing scale.
  • The most credible growth strategy is migration toward ibuprofen-only, pseudoephedrine-based, nasal-delivery, or other non-oral-phenylephrine products.

FAQs

Is ibuprofen and phenylephrine hydrochloride the same as ibuprofen and pseudoephedrine?

No. Ibuprofen is the analgesic in both combinations, but phenylephrine and pseudoephedrine are different decongestants. Pseudoephedrine has stronger commercial relevance as an oral decongestant but is subject to greater retail and legal controls in the United States.

Can ibuprofen and phenylephrine products still be sold in the United States?

Existing products may remain on the market while FDA’s administrative process proceeds, subject to applicable regulatory requirements. The long-term status depends on FDA’s final action concerning oral phenylephrine.

Does FDA’s phenylephrine action affect ibuprofen tablets?

No. The action concerns oral phenylephrine’s decongestant status. Ibuprofen-only OTC products are not eliminated by that action.

Are ibuprofen and phenylephrine products prescription drugs?

Most products are OTC medicines, but classification depends on the specific product, country, formulation, labeling, and regulatory pathway.

Is the combination commercially attractive for a generic manufacturer?

It can be attractive where demand is strong and the product remains legally marketable, but margins are constrained by private-label competition and low manufacturing costs. In the United States, oral phenylephrine regulatory risk materially reduces the attractiveness of new capacity dedicated to the combination.

References

  1. U.S. Food and Drug Administration. (2023). Nonprescription drugs advisory committee meeting: Oral phenylephrine. https://www.fda.gov
  2. Reckitt Benckiser Group plc. (2023). Annual report and financial statements 2023. https://www.reckitt.com
  3. Haleon plc. (2023). Annual report and financial statements 2023. https://www.haleon.com
  4. Kenvue Inc. (2023). Annual report 2023. https://www.kenvue.com
  5. Perrigo Company plc. (2023). Annual report 2023. https://www.perrigo.com
  6. U.S. Food and Drug Administration. (2024). Proposed order to amend the over-the-counter monograph for nasal decongestants. https://www.fda.gov
  7. U.S. Congress. (2005). Combat Methamphetamine Epidemic Act of 2005, Pub. L. No. 109-177.
  8. United States Patent and Trademark Office. (2024). Patent term adjustment and patent term. https://www.uspto.gov
  9. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/orange-book-data-files

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.